Loading organizations...
Key people at AdoraPet Biosciences.
AdoraPet Biosciences was founded in 2022 by Richard Chin (Co-Founder and Chairman of the Board of Directors).
AdoraPet Biosciences is a Burlingame, California-based biotechnology enterprise that develops advanced genomics and genetic engineering solutions to create healthier, cancer-free, and hypoallergenic companion animals for the consumer market. The organization specifically utilizes modern gene-editing technologies, including CRISPR, to fundamentally engineer pets that do not trigger human allergies or shed excessively within household environments. Operating exclusively within the specialized veterinary biosciences and companion pet care sector, the firm targets prospective pet owners seeking disease-resistant companion animals with highly specific, scientifically modified genetic traits. The company's executive leadership team brings significant veterinary pharmaceutical and commercial development experience from Kindred Biosciences, a prominent animal health business that was previously acquired by global industry leader Elanco. To advance the commercial application of companion animal biotechnology, AdoraPet Biosciences was established by co-founders Dr. Richard Chin and Dr. Bairu.
Key people at AdoraPet Biosciences.
AdoraPet Biosciences was founded in 2022 by Richard Chin (Co-Founder and Chairman of the Board of Directors).
AdoraPet Biosciences is a biotechnology startup based in San Mateo, California, developing CRISPR-based gene editing technologies to create healthier, longer-living dogs and cats free from cancer and allergies.[2][3][5] The company targets pet owners by editing genes at the egg stage or via insertion to eliminate disease-causing mutations, addressing common pet health issues that shorten lifespans and cause owner allergies.[1][2][4] It solves the problem of pet mortality from cancer (affecting ~50% of dogs and 90% of cats over age 10) and allergies, aiming to extend pet lifespans by 30-50% while boosting owner-pet bonding time.[3][4]
Launched around 2022, AdoraPet sought $5 million via crowdfunding under Regulation CF, as filed with the SEC, indicating early-stage growth momentum through equity crowdfunding on platforms like DealMaker.[3][4][5]
AdoraPet Biosciences emerged in late 2022 from a collaboration between genomics pioneer George Church—a Harvard professor known for advancing CRISPR—and executives from KindredBio, a pet biotech acquired by Elanco.[2][1] Key figures include a serial biotech entrepreneur who founded KindredBio (NASDAQ:KIN), served as Genentech's Head of Clinical Research, and led other ventures like Infinita Life Science (anti-aging therapies) and Bio Usawa (affordable cancer therapies); he now acts as founder and board member of AdoraPet.[1]
The idea stemmed from Church's expertise in genome engineering and the former KindredBio team's pet therapeutics experience, pivoting to preventive gene editing for companion animals.[2] A pivotal moment was their December 2022 SEC Form C filing to raise funds via crowdfunding, marking formal launch and early investor traction amid rising interest in designer pets.[3][5]
AdoraPet rides the CRISPR pet editing wave, fueled by falling gene-editing costs and surging $100B+ global pet industry spending (projected to hit $150B by 2030), where owners treat pets like family amid aging populations.[2][3] Timing aligns with regulatory progress (e.g., FDA's gene-edited animal approvals) and consumer demand for "designer" hypoallergenic/longevity pets, mirroring human longevity biotech trends.[1][2]
Market forces like post-pandemic pet adoptions (up 20%) and vet shortages favor preventive tech over reactive care.[3] AdoraPet influences the ecosystem by normalizing CRISPR in consumer biotech, potentially accelerating vet genomics startups and ethical debates on animal editing.[2][4]
AdoraPet's crowdfunding success signals strong early validation; next steps likely include prototype litters, FDA veterinary biologics clearance, and partnerships with breeders/vets by 2026-2027.[3][5] Trends like AI-optimized CRISPR (e.g., Church's influence) and pet humanization will propel growth, with potential $1B+ valuation if first allergy-free breeds launch.[2]
Influence may evolve from niche innovator to pet health leader, akin to KindredBio's path, reshaping how biotech extends companion animal lifespans and owner joy—echoing its mission for healthier, cancer-free pets.[1][4]
